Literature DB >> 29790128

Evidence That the Length of Bile Loop Determines Serum Bile Acid Concentration and Glycemic Control After Bariatric Surgery.

Adriana Mika1,2, Lukasz Kaska3, Monika Proczko-Stepaniak3, Agnieszka Chomiczewska1, Julian Swierczynski4,5, Ryszard T Smolenski4, Tomasz Sledzinski6.   

Abstract

BACKGROUND: Bariatric surgery contributes to the improvement in glucose metabolism that may be related to a postoperative increase in serum bile acids (BAs). Three commonly used types of bariatric procedures, laparoscopic sleeve gastrectomy (LSG) (without creation of a bile loop), Roux-en-Y gastric bypass (RYGB), and omega-loop gastric bypass (OLGB) (with creation of shorter 100-150 cm and longer 200-280 cm bile loops, respectively), differ in their effects on glycemic control. The aim of the study was to compare the effects of various bariatric procedures on serum BA concentration and glucose homeostasis.
METHODS: Serum BAs in 26 obese patients were determined by liquid chromatography-mass spectrometry prior to bariatric surgery, as well as 4 days and 3 months thereafter.
RESULTS: Four days after the surgery, serum concentrations of BAs in LSG and OLGB groups were similar as prior to the procedure, and a slight decrease in serum BAs was observed in the RYGB group. Serum BA level in the LSG group remained unchanged also at 3 months after the surgery, whereas a significant 0.5- and 3-fold increase in this parameter was noted in the RYGB and OLGB groups, respectively. Serum concentration of BAs correlated positively with the length of the bile loop (R = 0.47, p < 0.05).
CONCLUSION: The evident improvement of glycemic control observed 3 months after OLGB might be associated with a postoperative increase in serum BAs, resulting from their better absorption from the longer bile loop. However, the changes in serum BAs probably had little or no impact on insulin sensitivity improvement at 4 days post-surgery.

Entities:  

Keywords:  Bariatric surgery; Bile acids; Glucose metabolism; Liquid chromatography-mass spectrometry; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2018        PMID: 29790128     DOI: 10.1007/s11695-018-3314-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  36 in total

Review 1.  Medical consequences of obesity.

Authors:  George A Bray
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

2.  Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats.

Authors:  B S Reddy; K Watanabe; J H Weisburger; E L Wynder
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

Review 3.  Cardiovascular benefits of bariatric surgery in morbidly obese patients.

Authors:  V G Athyros; K Tziomalos; A Karagiannis; D P Mikhailidis
Journal:  Obes Rev       Date:  2011-02-23       Impact factor: 9.213

4.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.

Authors:  Mitsuhiro Watanabe; Sander M Houten; Chikage Mataki; Marcelo A Christoffolete; Brian W Kim; Hiroyuki Sato; Nadia Messaddeq; John W Harney; Osamu Ezaki; Tatsuhiko Kodama; Kristina Schoonjans; Antonio C Bianco; Johan Auwerx
Journal:  Nature       Date:  2006-01-08       Impact factor: 49.962

5.  Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery.

Authors:  Malin Werling; Royce P Vincent; Gemma F Cross; Hanns-Ulrich Marschall; Lars Fändriks; Hans Lönroth; David R Taylor; Jamshid Alaghband-Zadeh; Torsten Olbers; Carel W Le Roux
Journal:  Scand J Gastroenterol       Date:  2013-09-18       Impact factor: 2.423

6.  Biliopancreatic limb plays an important role in metabolic improvement after duodenal-jejunal bypass in a rat model of diabetes.

Authors:  Tomohiro Miyachi; Munenori Nagao; Chikashi Shibata; Yoshiro Kitahara; Naoki Tanaka; Kazuhiro Watanabe; Takahiro Tsuchiya; Fuyuhiko Motoi; Takeshi Naitoh; Michiaki Unno
Journal:  Surgery       Date:  2016-01-06       Impact factor: 3.982

7.  A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass.

Authors:  Glenn S Gerhard; Amanda M Styer; G Craig Wood; Stephen L Roesch; Anthony T Petrick; Jon Gabrielsen; William E Strodel; Christopher D Still; George Argyropoulos
Journal:  Diabetes Care       Date:  2013-07       Impact factor: 19.112

8.  Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity.

Authors:  Ricardo V Cohen; Jose C Pinheiro; Carlos A Schiavon; João E Salles; Bernardo L Wajchenberg; David E Cummings
Journal:  Diabetes Care       Date:  2012-07       Impact factor: 19.112

Review 9.  Physiological and molecular responses to bariatric surgery: markers or mechanisms underlying T2DM resolution?

Authors:  Chelsea R Hutch; Darleen A Sandoval
Journal:  Ann N Y Acad Sci       Date:  2016-09-26       Impact factor: 6.499

10.  Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding.

Authors:  Samantha Scholtz; Alexander D Miras; Navpreet Chhina; Christina G Prechtl; Michelle L Sleeth; Norlida M Daud; Nurhafzan A Ismail; Giuliana Durighel; Ahmed R Ahmed; Torsten Olbers; Royce P Vincent; Jamshid Alaghband-Zadeh; Mohammad A Ghatei; Adam D Waldman; Gary S Frost; Jimmy D Bell; Carel W le Roux; Anthony P Goldstone
Journal:  Gut       Date:  2013-08-20       Impact factor: 31.793

View more
  9 in total

1.  The Effect of One Anastomosis Gastric Bypass on Branched-Chain Fatty Acid and Branched-Chain Amino Acid Metabolism in Subjects with Morbid Obesity.

Authors:  Alicja Pakiet; Maciej Wilczynski; Olga Rostkowska; Justyna Korczynska; Patrycja Jabłonska; Lukasz Kaska; Monika Proczko-Stepaniak; Ewa Sobczak; Piotr Stepnowski; Faidon Magkos; Tomasz Sledzinski; Adriana Mika
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

Review 2.  Randomized Controlled Trial of One Anastomosis Gastric Bypass Versus Roux-En-Y Gastric Bypass for Obesity: Comparison of the YOMEGA and Taiwan Studies.

Authors:  Wei-Jei Lee; Owaid M Almalki; Kong-Han Ser; Jung-Chien Chen; Yi-Chih Lee
Journal:  Obes Surg       Date:  2019-09       Impact factor: 4.129

3.  Variation in Small Bowel Length and Its Influence on the Outcomes of Sleeve Gastrectomy.

Authors:  Owaid M Almalki; Tien-Chou Soong; Wei-Jei Lee; Jung-Chien Chen; Chun-Chi Wu; Yi-Chih Lee
Journal:  Obes Surg       Date:  2020-09-11       Impact factor: 4.129

4.  One-anastomosis gastric bypass modulates the serum levels of pro- and anti-inflammatory oxylipins, which may contribute to the resolution of inflammation.

Authors:  Ivan Liakh; Agata Janczy; Alicja Pakiet; Justyna Korczynska; Monika Proczko-Stepaniak; Lukasz Kaska; Tomasz Sledzinski; Adriana Mika
Journal:  Int J Obes (Lond)       Date:  2021-11-03       Impact factor: 5.095

Review 5.  Bariatric Surgery in NAFLD.

Authors:  Mahak Chauhan; Kuldeep Singh; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2022-01-04       Impact factor: 3.199

6.  What Is the Efficacy of Short Length of Biliopancreatic Limb in One-Anastomosis Gastric Bypass? A Systematic Review and Meta-analysis of Short-Term Results.

Authors:  Yichen Li; Yijie Gu; Yujia Jin; Zhongqi Mao
Journal:  Obes Surg       Date:  2022-04-24       Impact factor: 3.479

7.  Changes in fasting bile acid profiles after Roux-en-Y gastric bypass and sleeve gastrectomy.

Authors:  Chunlan Zhang; Jingjing Zhang; Zhiguang Zhou
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

8.  Serum free fatty acid levels and insulin resistance in patients undergoing one-anastomosis gastric bypass.

Authors:  Ivan Liakh; Monika Proczko-Stepaniak; Maciej Sledzinski; Adriana Mika
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-07-13       Impact factor: 1.195

9.  One Anastomosis Gastric Bypass Reconstitutes the Appropriate Profile of Serum Amino Acids in Patients with Morbid Obesity.

Authors:  Lukasz P Halinski; Alicja Pakiet; Patrycja Jablonska; Lukasz Kaska; Monika Proczko-Stepaniak; Ewa Slominska; Tomasz Sledzinski; Adriana Mika
Journal:  J Clin Med       Date:  2019-12-31       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.